Clinical Trials Logo

Targeted Therapy clinical trials

View clinical trials related to Targeted Therapy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02504346 Active, not recruiting - Lung Cancer Clinical Trials

AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies

TREM
Start date: August 2015
Phase: Phase 2
Study type: Interventional

Phase II, single-arm study to assess the safety and efficacy of AZD9291 (80 mg, orally, once daily) in second-line (or later) patients with EGFR mutation-positive, locally advanced or metastatic NSCLC, who have progressed following treatment with an approved epidermal growth factor tyrosine kinase inhibitor agent.